Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Tesco Reveals Dental Map Of Britain
Research from a survey by Tesco Dental Insurance has revealed Brits are finding it increasingly difficulty to find an NHS dentist. The results also show that rising dental costs are putting people off visiting the dentist.

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study For MoxDuo(TM) IV Pain Therapy
QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. Data from this study will serve as a significant predictor of MoxDuo(TM) IV"s clinical benefits and provide guidance for the design of further clinical trials leading to submission of an NDA to the US Food and Drug Administration (FDA) within the next three years.
News of the day
Study Links Recurrence Of Abnormal Cervical Cells To Age, Treatment Type
Older women, women with a higher grade of precancerous cells and women who undergo a freezing procedure known as cryotherapy to remove abnormal cervical cells are at a higher risk than other groups that the problem cells will return or develop into cervical cancer, according to a study published in the Journal of the National Cancer Institute, Reuters reports. For the study, Joy Melnikow of the University of California-Davis and colleagues compared 37,000 women who were treated for cervical intraepithelial neoplasia -- abnormal cervical cells -- from 1986 through 2000 with 71,000 women who had no history of abnormal cervical cells.The researchers found that the risk of cervical cancer and recurrence of medium to severe degrees of CIN was highest for women who were older than age 40, who had been previously treated for severe CIN or whose abnormal cells were treated using cryotherapy. The women underwent cone biopsies a surgical procedure to remove abnormal cells were least likely to have a recurrence of CIN. According to Melnikow, recurrence was most likely to occur within the first six years after treatment. Melnikow said that women who have been treated surgically have higher risks of bleeding and preterm labor. Therefore, younger women who are planning to become pregnant might prefer cryotherapy, she said, adding that younger women"s "risk of recurrence is lower, and a recurrence can be treated again" (Steenhuysen, Reuters, 5/12).
Health Insurance

CardioFocus Receives CE Mark For Atrial Fibrillation Ablation Catheter

CardioFocus, Inc. announced that it has received a CE Mark allowing the company to commence European marketing of the Endoscopic Ablation System (EAS) to treat patients with atrial fibrillation. The EAS is the latest generation, percutaneous catheter system that has been used clinically to treat patients with atrial fibrillation. This novel device incorporates both a micro-endoscope and light energy fibers to give physicians the capacity to actually see within the heart, and for the first time, visually direct the application of energy through a catheter. "We are grateful for the thorough review and the rapid response we received from our notified body," said Burke Barrett, CardioFocus VP of Clinical and Regulatory Affairs. Atrial Fibrillation is a common cardiac arrhythmia affecting several million people in Europe and over 2.5 million more in the United States. Symptoms can range from weakness and dizziness to more profound morbidity including stroke. Researchers believe that the considerable incidence and prevalence of the disease are increasing due to aging populations worldwide. Professional medical societies have endorsed the use of catheter ablation therapy when anti-arrhythmic drugs are ineffective, which can occur more than half the time. "The EAS represents a new era for catheter ablation of this complex arrhythmia. The CardioFocus device provides the electrophysiologist with a direct view of the cardiac anatomy that simply has not been available using other catheters. I believe that seeing the true orientation of the anatomy in full color and in real time, combined with the ability to safely and reliably deliver energy to the right target, increases the likelihood of delivering effective therapy," said Vivek Y. Reddy, MD, Director of Electrophysiology Laboratories at The Mount Sinai Medical Center in New York City. The EAS was the subject of several presentations at the recent Heart Rhythm Society meeting in Boston, highlighting excellent clinical results, simplified ease of use, reduced x-ray exposure and shortened procedure times. The CardioFocus device was also featured on the scientific program at the EuroPace meeting in Berlin in June, and will be prominent on the program at the Europe AF meeting in London in September. Since clinical results were reported at the 2009 Boston AF Symposium, physician interest in visually guided catheter ablation has been accelerating dramatically. As reported by several top centers, current catheter therapies are effective in barely 50% of patients receiving a single treatment. "CE Marking for our product highlights the great progress our company has made; our entire group has been dedicated to achieving this milestone. This facilitates more ambitious international research and European commercialization of our device. Cardiac electrophysiology is a focused area of medicine where a small company can make a big impact with the right product. Our interactions with well known specialists worldwide have provided enormous encouragement," commented Stephen W. Sagon, CardioFocus President and CEO. CardioFocus, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009